FAST NEWS: Ascletis Pharma’s Cancer Drug Eyes U.S. with New Drug Application
The latest: Ascletis Pharma Inc. (1672.HK) announced it has filed an Investigational New Drug (IND) application in the U.S. for its self-house developed oral PD-L1 small molecule inhibitor, ASC61, for the…
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
